Ursochol 300    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease1

67. Polycystic kidney disease    [ 186 clinical trials,   196 drugs,   (DrugBank: 47 drugs),   35 drug target genes,   146 drug target pathways]
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 186 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-003207-19-NL
(EUCTR)
29/11/201308/08/2013Trial to investigate the effect of ursodeoxycholic acid as a treatment of symptoms in polycystic liver disease: the CURSOR-trialAn international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers - The CURSOR trial Patients suffering from symptomatic polycystic liver disease (PLD) with underlying diagnosis of isolated polycystic liver disease (PCLD) or autosomal dominant kidney disease (ADPKD);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: URSOCHOL 300Radboud University Nijmegen Medical CenterNULLNot RecruitingFemale: yes
Male: yes
34Phase 4Spain;Netherlands